Drug intelligence / Profile preview

MMB-102

Development stage: Unknown
Lead developer: MediMabBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MMB-102 is a monoclonal antibody drug candidate developed by MediMabBio. It acts as an agonist of GITR (Glucocorticoid-induced tumor necrosis factor receptor-related protein), an immune checkpoint molecule. The drug is being investigated for its potential use in the treatment of neoplasms, with a particular focus on liver cancer. Its mechanism involves stimulating GITR to enhance anti-tumor immune responses, which may help overcome immunosuppression in the tumor microenvironment. As of May 2025, MMB-102 remains at the discovery or preclinical stage and has not yet entered clinical trials[1][7].

Targets

TNFRSF18 (GITR)

Beyond the preview

Go deeper on MMB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMB-102.

Explore the full profile